Flu Fighter: Nanoparticle-Based Vaccine Effective in Preclinical Trials

Updated May 26, 2021

Various media outlets reported on UB-led research that found an experimental nanoparticle-based flu vaccine consisting of disease-fighting proteins was proven effective in preclinical studies. The technology could boost the effectiveness and accelerate the production of seasonal flu vaccines. The study was co-authored by Jonathan F. Lovell, PhD, associate professor of biomedical engineering, and Bruce A. Davidson, PhD, research associate professor of anesthesiology, and led by Zachary Robert Sia, a trainee in the doctoral program in biomedical engineering.